Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
about
Interferon lambda: a new sword in cancer immunotherapyInterferon alpha for the adjuvant treatment of cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaAnalysis of the genome to personalize therapy for melanomaAssociations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutationsA 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoireChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective ImmunotherapyLong-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsAnticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12The past, present and future of immunotherapy against tumorImpact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing researchA clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic markerToxicities of Immunotherapy for the PractitionerUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.PD-1 and PD-L1 antibodies for melanomaTwo new trifunctional antibodies for the therapy of human malignant melanomaNivolumab in melanoma: latest evidence and clinical potentialDacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trialSkin mapping with punch biopsies for defining margins in melanoma: when you don't know how far to goThe National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis.Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]Molecular staging for patients with malignant melanoma.Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)Malignant melanoma (non-metastatic).Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.VARIABLE SELECTION FOR REGRESSION MODELS WITH MISSING DATA.Melanoma in pediatric, adolescent, and young adult patients.Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter studyEffective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.The use of immunotherapy in the treatment of melanomaRecent progress in cytokine therapy for renal cell cancer: a case for the European Organization for Research and Treatment of Cancer adjuvant cytokine trial in patients with poor-risk renal cell cancer after maximum debulking surgery.Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulationTreatment of malignant melanoma.Immune and gene therapy for melanoma, and the immunobiology of melanoma.Immunotherapy for solid tumors--a review for surgeons.STAT signaling in the pathogenesis and treatment of cancer
P2860
Q21296797-98F512D5-21E0-445B-894A-159A1DD31434Q24201908-32D448CE-178B-4415-BBDD-A3A6E4937E08Q24235257-4D6543CC-04C7-4D6F-A059-F4F029B8600AQ24601008-E86B683C-3503-4D52-950B-7B420965E630Q24630954-A6C439A6-BE4D-4C50-8A1E-CD8909E22234Q24654139-08307102-350B-420D-9EBC-ECE5E7951505Q26770492-0828930F-FC6A-4FC1-BCDA-9F2573AF4248Q26771449-4C4BF00A-8203-43DB-971A-3EA441DCAEA8Q26775546-1A83F95E-3A4B-486B-B618-61C0AFAC8CF0Q26796316-C43277F3-2CDD-428E-8179-499263535F12Q26799896-875068D8-50C7-4BA1-8EF2-47A5B27C823CQ26866122-DDE0EAB7-A6F3-4329-B705-AF65576414DCQ26991675-54016CF2-FB8D-49B5-BC2F-DAF1E6EA207AQ27008140-FA863087-6917-434F-8296-6BEF4874DF3FQ27691824-FA8CF39E-DB2A-431D-B4E1-022F5598C14EQ28081882-2FCAA0C9-AE13-4097-8D28-1F8D2B604346Q28236224-EECF7CDD-9ADC-42FF-A869-0EBE79D7E98AQ28258598-5D9FCAA5-E26A-4EB7-B8DA-458417FBE067Q28362951-A00C8251-B870-4F48-BEA5-FA56FBFB6A46Q28364878-6D0DACED-F824-41BA-BABF-CB3DC6557193Q30436479-21F57D39-A656-4AD3-ADB0-9607A6007F65Q31995716-D5CCA189-8636-4FB1-B58D-9351FDB18343Q32159956-46B4178B-C796-4888-9137-4D3B4D7AFFFAQ33234917-ED18765C-54AE-43D8-89E8-7A79A6FFD56AQ33306116-0438D8D5-5D7E-481F-BE95-34B7F74E6A5AQ33338541-D1D353EF-4629-475D-8403-6FEF35791EB1Q33448157-77FE2FAE-E6D4-400F-B0E9-F78355404333Q33502404-B348FB77-5DFF-414B-92F2-F728FB61C5CCQ33545644-93C06798-B8D5-4849-B270-C2611507CD0FQ33554622-1E010780-8A50-4AFA-BA37-4186CD9EEF4CQ33557548-09C9986C-D770-48EC-B200-2D3AA3F2E8E0Q33567330-ABCEB29F-8F21-4BD1-B94D-15FBCF8D2A93Q33586122-D6908D17-19FE-4112-93E1-0169B934F4C2Q33593858-687CE534-074A-41EE-95EC-8E25C388F679Q33610888-952FD14B-B7FB-4BDC-A4B4-AD669A0CAC2BQ33631126-46477543-B4D7-4CC9-B936-B0E208A9B829Q33689227-F0974E6F-9C11-4D57-B007-E0E8362208B2Q33706946-9821B45E-D21B-4BFE-AC5E-4153A12CDAEDQ33709232-086068C4-7392-4D16-B2AF-43017CEBCD00Q33712802-8888E412-47A6-4776-B8A8-A0C49232B13D
P2860
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@ast
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@en
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@nl
type
label
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@ast
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@en
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@nl
prefLabel
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@ast
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@en
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@nl
P2093
P356
P1476
Interferon alfa-2b adjuvant th ...... Oncology Group Trial EST 1684.
@en
P2093
E C Borden
J M Kirkwood
M H Strawderman
M S Ernstoff
P356
10.1200/JCO.1996.14.1.7
P407
P577
1996-01-01T00:00:00Z